Plaque Psoriasis
Conditions
Brief summary
The main purpose of this study is to learn more about the safety and side effects of DC-806 when given by mouth to healthy participants and participants with Chronic Plaque Psoriasis. The study will have three parts. Each participant will enroll in only one part. For each participant, Part 1 will last up to 14 weeks, Part 2 will last up to 12 weeks, Part 3 will last up to 11 weeks including screening and follow-up.
Interventions
OTHERPlacebo
administered orally.
DRUGDC-806
administered orally.
Sponsors
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy Subjects (Parts 1 and 2) * Men and women participants must be between 18-55 years inclusive, at the time of informed consent. * Female participants must either be of non-childbearing potential or if of childbearing potential, must not be pregnant, breast feeding or lactating and use a highly effective birth control method during treatment and for 90 days following last administered dose. In addition, male partners of female subjects of childbearing potential must use highly effective contraception for 90 days following the last administered dose * Male participants who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after their last dose of IMP. * Participants must agree not to donate semen or ova/oocytes during the study and for 90 days after the last dose of IMP. * Participants must have a body mass index (BMI) ≥ 18 and ≤ 35 kg/m2. * Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator or designee. Participants with Psoriasis (Part 3) * Men and women Participants must be between 18-65 years inclusive, at the time of informed consent. * Participants must have a documented diagnosis of plaque psoriasis for ≥ 6 months prior to screening. * Physicians Global Assessment (PGA) of 2/3 i.e. mild or moderate plaque psoriasis at baseline. * Body Surface Area (BSA) ≥3% at baseline. * A minimum of 2 psoriatic lesions of at least 2 cm x 2 cm at baseline, with at least 1 plaque in a site suitable for biopsy. * Female participants must either be of non-childbearing potential or if of childbearing potential, must not be pregnant, breast feeding or lactating and use a highly effective birth control method during treatment and for 90 days following last administered dose. In addition, male partners of female subjects of childbearing potential must use highly effective contraception for 90 days following the last administered dose. * Male participants who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved method of highly effective contraception from the time of informed consent until 90 days after their last dose of IMP. * Participants must have a body mass index (BMI) ≥ 18 and ≤ 36 kg/m2.
Exclusion criteria
Healthy Subjects (Parts 1 and 2) * History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the subject's safety during the clinical study or expose the subject to undue risk as judged by the Investigator or designee. * After 10 minutes supine rest at the time of screening or prior to dosing on Day 1, any vital signs values outside the following ranges: * Systolic blood pressure \<90 or \>150 mmHg, or * Diastolic blood pressure \<50 or \>95 mmHg, or * Pulse \<40 or \>90 bpm * Any clinically significant abnormalities in resting ECG at the time of screening or pre-dose Day 1 including prolonged QTcF (\>450 ms for males; \>470 ms for females using the mean of triplicate ECG's) and cardiac arrhythmias, as judged by the Investigator or designee. * Clinically significant abnormalities in renal function: • eGFR \<60 mL/min * Clinically significant abnormalities in liver function: * Bilirubin \>1.5 x ULN * Aminotransferases \>1.5 x ULN * ALP \>1.5 x ULN * History of latent TB, active tuberculosis, or a positive QuantiFERON® TB Gold result at screening. Patients with an indeterminate QuantiFERON® TB Gold result at screening will be allowed one retest; if not negative on retesting, the subject will be excluded. * Females who are pregnant, breast feeding or plan to be pregnant during the study period or 90 days after. * Female subjects with a positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[hCG\]) at screening or within 24 h prior to the first administration of IMP. * Positive serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCV Ab) or human immunodeficiency virus (HIV) 1 and/or 2 antibodies at screening. * Part 2 Only: Presence of active suicidal ideation or positive suicide behaviour using the Baseline/Screening version of the Columbia Suicide Severity Rating Scale (C-SSRS) and with either of the following criteria: * History of a suicide attempt within the 5 years prior to the Screening Visit. Subjects with a history of a suicide attempt more than 5 years ago should be evaluated by a mental healthcare professional (eg, locally licensed psychiatrist, psychologist, or master's level therapist) before enrolling into the study. * Suicidal ideation in the past month prior to the Screening Visit as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Baseline/Screening version of the C-SSRS. Participants with Psoriasis (Part 3) * History or presence of any clinically relevant acute or chronic medical or psychiatric condition other than psoriasis that could interfere with the patient's safety during the clinical study or expose the patient to undue risk as judged by the Investigator or designee. * A diagnosis of non-plaque psoriasis. * Plaque psoriasis restricted to the scalp, palms, soles and face. * Pustular, erythrodermic, inverse, and guttate psoriasis * Drug-induced psoriasis (i.e., new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium) * Diagnosis of psoriatic arthritis, uveitis, inflammatory bowel disease, or other immune-mediated conditions that are commonly associated with psoriasis for which a subject requires current systemic (oral, SC, or IV) (including corticosteroids, immunosuppressants, biologics) immunosuppressant medical treatment * Treatment with biologics within 5 half-lives (if known) or 6 months prior to dosing on Day 1, whichever is longer * Has received any systemic immunosuppressants (e.g. Methotrexate, cyclosporine, hydroxyurea, and tacrolimus) or anakinra within 4 weeks of the first administration of study medication. * Has received phototherapy or any systemic medications/treatments that could affect psoriasis or PGA evaluation (including, but not limited to, oral or injectable corticosteroids, retinoids, psoralens, sulfasalazine, hydroxyurea, apremilast, or fumaric acid derivatives) within 4 weeks of the first administration of study medication * Has used topical medications/treatments that could affect psoriasis or PGA evaluation (including, but not limited to, corticosteroids, anthralin, calcipotriene, topical vitamin D derivatives, retinoids, tazarotene, picrolimus, and tacrolimus) within 2 weeks of the first administration of study medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug. | Baseline Up To 7 Weeks | A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module. |
| Part 2: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug. | Baseline Up To 7 Weeks | A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module. |
| Part 3: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug. | Baseline Up To 11 Weeks | A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1, PK: First-order elimination half-life (T1/2) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Half-life (T1/2) DC-806 |
| Part 2, PK: Maximum Observed Concentration (Cmax) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Cmax of DC-806 |
| Part 2, PK: Area Under the Concentration Versus Time Curve (AUC) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: AUC of DC-806 |
| Part 1, Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of DC-806. | Pre-dose up-to 48 hours post-dose | PK: Cmax of DC-806. |
| Part 2, PK: First-order elimination half-life (T1/2) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Half-life (T1/2) DC-806 |
| Part 3, PK: Maximum Observed Concentration (Cmax) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Cmax of DC-806 |
| Part 3, PK: Ctrough of DC-806 | Pre-dose up-to 48 hours post-dose | pre-dose of DC-806 |
| Part 2, PK: Time to reach maximum observed (Tmax) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Tmax of DC-806 |
| Part 1, PK: Area Under the Concentration Versus Time Curve (AUC) of DC-806. | Pre-dose up-to 48 hours post-dose | PK: AUC of DC-806. |
| Part 1, PK: Time to reach maximum observed (Tmax) of DC-806 | Pre-dose up-to 48 hours post-dose | PK: Tmax of DC-806 |
Countries
United Kingdom
Outcome results
None listed